Skip to main content

Houston Ranks Among Leading Life Sciences Markets: CBRE Report

Published Jun 15, 2022 by A.J. Mistretta

levit green.jpg

A rendering of Levit Green

Aided by a high percentage of PhDs and a low cost of living, Houston ranks No. 13 in a new analysis of the nation’s top 25 life sciences markets from real estate firm CBRE. 

The report sheds light on the growth of life sciences hubs beyond the traditional coastal markets such as Boston and San Diego. Houston is getting a boost from the growing Texas Medical Center and an influx of venture capital earmarked for life sciences research. 

Job growth in life sciences professions – from bioengineers and biochemists to microbiologists and data scientists – expanded by 79% over the last two decades to roughly 500,000. In comparison, the overall U.S. job growth rate in that span was 8%, according to CBRE. That surge in life sciences jobs boosted mainstay markets such as Boston and San Francisco as well as emerging hubs including Nashville, Salt Lake City and Houston. 

The report suggests that Houston’s life sciences labor market offers an attractive combination of affordability and a particularly strong PhD talent pool. Major research universities and medical institutions such as the UT School of Public Health and Baylor College of Medicine boosted the city’s ranking ahead of other Texas markets in CBRE’s analysis. 

“Houston’s favorable business climate and cost of living, combined with the size of its scientific talent pool and medical institutions, make it an attractive market for life sciences industry expansion,” said Scott Carter, Senior Vice President, Life Sciences & Healthcare at CBRE in Houston. “Houston is projected to lead the nation in population growth over the next five years, which will only strengthen the appeal of its labor market.” 

Houston ranks No. 1 in the nation when it comes to life sciences wages relative to the cost of living, making it more attractive for life sciences professionals to enjoy a high quality of life. PhDs account for 18.5% of the 1,300 Biological and Biomedical Sciences degrees issued from the Houston MSA annually – the highest concentration nationwide. And Houston produces 4.2% of such PhDs in the U.S. – more than all but a few major life sciences markets do. 

“Millions of square feet and billions of dollars of life sciences development is underway or planned in Houston to break down longtime silos between commercial, academic, and medical sectors,” Carter said. “Leveraging the unmatched scale of the Texas Medical Center, these new moon-shot investments are building a launchpad to rocket Space City into a new era as a global hub for scientific and human progress.” 

Highlighting the rapid investment in the city’s innovation ecosystem, Houston has one of the country’s fastest-growing pipelines for life sciences venture capital funding, which increased by 937% in the last five years – nearly three times the nationwide increase of 345%. 

Source: CBRE

To develop the ranking, CBRE assessed each market against multiple criteria, including its number of life sciences jobs and graduates, life sciences’ share of each market’s overall job and graduate pool, number of doctorate degree holders in life sciences, and its concentration of jobs in the broader professional, scientific and technical services professions. 

A number of large-scale life sciences developments are currently in the works that will add significant amounts of new research, lab and office space to the existing market, including Levit Green and TMC3. Learn more about some of those projects. Click here to see the full CBRE report.

 

Related News

Health Care

University of Houston, Baylor College of Medicine to Launch Cutting-Edge Research Hub

8/26/24
The University of Houston (UH) and Baylor College of Medicine (BCM) have been awarded a $44.2 million grant from the National Center for Advancing Translational Research. This funding will support the establishment of a regional hub dedicated to advancing clinical and translational research.  Dubbed the Consortium for Translational and Precision Health (CTPH), the new hub will enhance collaboration between the two institutions and other clinical and research groups within the Texas Medical Center. The CTPH aims to expedite the translation of new technologies and discoveries into patient care and real-world impact, provide funding and resources to accelerate pilot projects and research initiatives and connect investigators with local healthcare organizations and government agencies that are dedicated to healthcare, clinical research and policy.  “Research is the engine empowering health care’s life-changing advancements,” said UH President Renu Khator, in a release. “This innovative hub will be a catalyst for groundbreaking discoveries and treatments that improve people’s quality of life. That’s what drives us at UH and we’re ecstatic to cofound a regional hub for change alongside Baylor.”  The hub will be led by BCM’s Christopher Amos, professor and director of the Institute for Clinical and Translational Research, and Dr. Fasiha Kanwal, professor of medicine and chief of the section of gastroenterology and hepatology, alongside UH’s Dr. Bettina M. Beech, clinical professor of population health and chief population health officer.  “The CTPH is a partnership that draws on strengths of both institutions, creating a rich multidisciplinary environment. It will act as the vehicle to enhance the infrastructure and resources needed to effectively conduct research and implement solutions to advance healthcare,” said Dr. Carolyn Smith, interim senior vice president and dean of research at BCM. “It will help implement and create ongoing core research activities that will support the clinical translational science at both institutions.”  This strategic partnership comes at a time when local institutions are intensifying efforts to advance critical research that will deliver vital healthcare solutions. The University of Texas MD Anderson Cancer Center and Rice University recently announced a collaboration to advance fundamental and translational cancer research and develop life-saving technologies. Additionally, a research initiative led by Rice University, in collaboration with MD Anderson, received an $18 million grant to improve tumor removal technology for breast, head and neck cancer.  Learn more about Houston’s Life Sciences industry. 
Read More
Life Sciences

Rice University Awarded $18 Million to Advance Tumor Removal Technology

8/16/24
A research initiative led by Rice University, in collaboration with The University of Texas MD Anderson, has received an $18 million grant from the Advanced Research Projects Agency for Health (ARPA-H). The funding, which will be distributed over five years, will support the development of a new system aimed at enhancing the accuracy of tumor removal in breast, and head and neck cancer.   Rice University was among eight institutions chosen to receive a share of the $150 million in grants announced earlier this week by the Biden-Harris administration. This funding is part of the ongoing Cancer Moonshot initiative, which seeks to halve the cancer death rate by 2047.   The Rice and MD Anderson research team has developed a groundbreaking cancer pathology system called AccessPath, which addresses a significant challenge surgeons face: accurately identifying the margin where a tumor ends, and healthy tissue begins. Leveraging advanced technologies, including a high-resolution microscope and advanced artificial intelligence algorithms, AccessPath enables surgeons to determine in real time whether they have completely removed a tumor during surgery.  “Because of its low cost, high speed, and automated analysis, we believe AccessPath can revolutionize real-time surgical guidance, greatly expanding the range of hospitals able to provide accurate intraoperative tumor margin assessment and improving outcomes for all cancer surgery patients,” Rebecca Richards-Kortum, a lead researcher on the project and director of the Rice360 Institute for Global Health Technologies, said in a news release.  According to ARPA-H, nearly two million Americans are diagnosed with cancer each year. Given the complexity and high cost of cancer treatment, AccessPath offers a promising solution by “reducing the number of repeat interventions, lowering cancer care costs and improving patient outcomes,” said Dr. Ana Paula Refinetti, an associate professor in the Breast Surgical Oncology department at MD Anderson and one of the lead researchers on the project.  This cutting-edge innovation stems from a strategic partnership established this summer between Rice University and MD Anderson. Through the Cancer Bioengineering Collaborative, the two institutions are working together to develop life-saving technologies and bioengineering strategies to enhance cancer research, diagnosis and treatment.  “AccessPath is exactly the kind of life-changing research and health care innovation we are proud to produce at Rice, where we’re committed to addressing and solving the world’s most pressing medical issues,” said Ramamoorthy Ramesh, Rice’s executive vice president for research. “Partnering with MD Anderson on this vital work underscores the importance of such ongoing collaborations with our neighbors in the world’s largest medical center.”  This award is yet another example showcasing Houston’s leadership in advancing critical, life-saving technologies.  Learn more about Houston’s life sciences industry. 
Read More

Related Events

Economic Development

State of the Texas Medical Center

The Greater Houston Partnership's State of the Texas Medical Center returns on Thursday, November 14! William F. McKeon, President and CEO of the Texas Medical Center, will deliver an annual address, discussing the…

Learn More
Learn More
Executive Partners